Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/53156
Tipo
PreprintDerechos de autor
Acceso abierto
Colecciones
- CDTS - Preprint [22]
- IOC - Preprint [149]
Metadatos
Mostrar el registro completo del ítem
THE ROLE OF NSP6 IN THE BIOGENESIS OF THE SARS-COV-2 REPLICATION ORGANELLE
Autor
Ricciardi, Simona
Guarino, Andrea Maria
Giaquinto, Laura
Polishchuk, Elena V.
Santoro, Michele
Di Tulio, Giuseppe
Wilson, Cathal
Panariello, Francesco
Soares, Vinicius C.
Dias, Suelen S. G.
Santos, Julia C.
Souza, Thiago Moreno L.
Fusco, Giovanna
Viscardi, Maurizio
Brandi, Sergio
Bozza, Patrícia T.
Polishchuk, Roman S.
Venditti, Rossella
Matteis, Maria Antonieta De
Guarino, Andrea Maria
Giaquinto, Laura
Polishchuk, Elena V.
Santoro, Michele
Di Tulio, Giuseppe
Wilson, Cathal
Panariello, Francesco
Soares, Vinicius C.
Dias, Suelen S. G.
Santos, Julia C.
Souza, Thiago Moreno L.
Fusco, Giovanna
Viscardi, Maurizio
Brandi, Sergio
Bozza, Patrícia T.
Polishchuk, Roman S.
Venditti, Rossella
Matteis, Maria Antonieta De
Afiliación
Telethon Institute of Genetics and Medicine, TIGEM, Pozzuoli (Naples) Italy / Dept. Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Italy.
Telethon Institute of Genetics and Medicine, TIGEM, Pozzuoli (Naples) Italy.
Telethon Institute of Genetics and Medicine, TIGEM, Pozzuoli (Naples) Italy.
Telethon Institute of Genetics and Medicine, TIGEM, Pozzuoli (Naples) Italy.
Telethon Institute of Genetics and Medicine, TIGEM, Pozzuoli (Naples) Italy.
Telethon Institute of Genetics and Medicine, TIGEM, Pozzuoli (Naples) Italy.
Telethon Institute of Genetics and Medicine, TIGEM, Pozzuoli (Naples) Italy.
Telethon Institute of Genetics and Medicine, TIGEM, Pozzuoli (Naples) Italy.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil / Universidade Federal do Rio de Janeiro. Programa de Imunologia e Inflamação. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnologico em Saúde. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Instituto Nacional de Ciência e Tecnologia em Inovação em Doenças de Populações Negligenciadas. Rio de Janeiro, RJ, Brasil.
Istituto Zooprofilattico Sperimentale del Mezzogiorno. 80055 Portici (Naples). Italy.
Istituto Zooprofilattico Sperimentale del Mezzogiorno. 80055 Portici (Naples). Italy.
Istituto Zooprofilattico Sperimentale del Mezzogiorno. 80055 Portici (Naples). Italy.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil.
Telethon Institute of Genetics and Medicine, TIGEM, Pozzuoli (Naples) Italy.
Telethon Institute of Genetics and Medicine, TIGEM, Pozzuoli (Naples) Italy / Dept. Molecular Medicine and Medical Biotechnology, University of Naples Federico II. Italy.
Telethon Institute of Genetics and Medicine, TIGEM, Pozzuoli (Naples) Italy / Dept. Molecular Medicine and Medical Biotechnology, University of Naples Federico II. Italy.
Telethon Institute of Genetics and Medicine, TIGEM, Pozzuoli (Naples) Italy.
Telethon Institute of Genetics and Medicine, TIGEM, Pozzuoli (Naples) Italy.
Telethon Institute of Genetics and Medicine, TIGEM, Pozzuoli (Naples) Italy.
Telethon Institute of Genetics and Medicine, TIGEM, Pozzuoli (Naples) Italy.
Telethon Institute of Genetics and Medicine, TIGEM, Pozzuoli (Naples) Italy.
Telethon Institute of Genetics and Medicine, TIGEM, Pozzuoli (Naples) Italy.
Telethon Institute of Genetics and Medicine, TIGEM, Pozzuoli (Naples) Italy.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil / Universidade Federal do Rio de Janeiro. Programa de Imunologia e Inflamação. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnologico em Saúde. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Instituto Nacional de Ciência e Tecnologia em Inovação em Doenças de Populações Negligenciadas. Rio de Janeiro, RJ, Brasil.
Istituto Zooprofilattico Sperimentale del Mezzogiorno. 80055 Portici (Naples). Italy.
Istituto Zooprofilattico Sperimentale del Mezzogiorno. 80055 Portici (Naples). Italy.
Istituto Zooprofilattico Sperimentale del Mezzogiorno. 80055 Portici (Naples). Italy.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil.
Telethon Institute of Genetics and Medicine, TIGEM, Pozzuoli (Naples) Italy.
Telethon Institute of Genetics and Medicine, TIGEM, Pozzuoli (Naples) Italy / Dept. Molecular Medicine and Medical Biotechnology, University of Naples Federico II. Italy.
Telethon Institute of Genetics and Medicine, TIGEM, Pozzuoli (Naples) Italy / Dept. Molecular Medicine and Medical Biotechnology, University of Naples Federico II. Italy.
Resumen en ingles
SARS-CoV-2, like other coronaviruses, builds a membrane-bound replication organelle (RO) to enable RNA replication1 23 . The SARS-CoV-2 RO is composed of double membrane 24 vesicles (DMVs) tethered to the endoplasmic reticulum (ER) by thin membrane connectors2 25 , but the viral proteins and the host factors involved are currently unknown. 26 Here we identify the viral non-structural proteins (NSPs) that generate the SARS-CoV-2 27 RO. NSP3 and NSP4 generate the DMVs while NSP6, through oligomerization and an 28 amphipathic helix, zippers ER membranes and establishes the connectors. The 29 NSP6ΔSGF mutant, which arose independently in the α, β, γ, η, ι, and λ variants of SARS30 CoV-2, behaves as a gain-of-function mutant with a higher ER-zippering activity. We 31 identified three main roles for NSP6: to act as a filter in RO-ER communication allowing 32 lipid flow but restricting access of ER luminal proteins to the DMVs, to position and 33 organize DMV clusters, and to mediate contact with lipid droplets (LDs) via the LD34 tethering complex DFCP1-Rab18. NSP6 thus acts as an organizer of DMV clusters and can 35 provide a selective track to refurbish them with LD-derived lipids. Importantly, both 36 properly formed NSP6 connectors and LDs are required for SARS-CoV-2 replication. Our 37 findings, uncovering the biological activity of NSP6 of SARS-CoV-2 and of other 38 coronaviruses, have the potential to fuel the search for broad antiviral agents.
Compartir